Search
methysergide (Sansert)
Tradename: Sansert.
Indications:
- migraine prophylaxis
Contraindications:
1) peripheral vascular disease
2) pulmonary disease
3) severe hypertension
4) phlebitis
5) serious infections
6) impaired renal or hepatic function
Dosage:
1) 4-8 mg PO QD
2) do NOT give continuously for more than 6 months
3) taper dose for 2-3 week period prior to discontinuation to avoid rebound headache
Tabs: 2 mg.
Adverse effects:
1) common (> 10%)
- insomnia, orthostatic hypotension, nausea/vomiting, abdominal pain, diarrhea, peripheral ischemia
2) less common (1-10%)
- heartburn, peripheral edema, tachycardia, bradycardia, rash
3) uncommon (< 1%)
- fibrosis, insomnia, overstimulation, drowsiness, mild euphoria, lethargy, depression, vertigo, unsteadiness, confusion, hyperesthesia, visual disturbances
4) other
- retroperitoneal fibrosis*
- pleural & pulmonary fibrosis*
- fibrotic* thickening of cardiac valves
- rebound headache may occur if methysergide is discontinued abruptly
* Fibrosis rarely occurs if therapy is interrupted for 3-4 weeks every 6 months
Interactions
drug interactions
General
anti-migraine agent
ergot alkaloid
Properties
MISC-INFO: elimination route LIVER
pregnancy-category X
D
safety in lactation -
Database Correlations
PUBCHEM correlations
References
- The Pharmacological Basis of Therapeutics, 9th ed.
Gilman et al, eds. Permagon Press/McGraw Hill, 1996
- Kaiser Permanente Northern California Regional Drug
Formulary, 1998
- Deprecated Reference